GRAND RAPIDS, Mich., Nov. 29 /PRNewswire/ -- The Center for Molecular Medicine (CMM) today announced its role as the first member of the Xceed Molecular (http://www.xceedmolecular.com; Wellesley, MA) collaborator program.
In this role, CMM is the first US site to offer Xceed Molecular's new Ziplex(R) system for gene expression analysis, giving researchers an important new tool in disease investigation and drug discovery. Analysis of gene expression enables critical insights into how diseases arise, progress and respond to new potential drugs and other therapies; the resultant markers of disease can be turned into clinical laboratory tests for diagnosis.
Recently launched at the Association for Molecular Pathology (http://www.amp.org) 2007 annual meeting, Xceed Molecular's Ziplex System is designed to perform complex molecular assays with a high level of accuracy, reproducibility and scalability at significantly lower cost than other options. The automated Ziplex System can test eight samples simultaneously with minimal hands-on time and rapid total result turnaround time.
The CMM is working with Xceed Molecular to demonstrate the utility and ease of use of the Ziplex System in its CLIA-certified, CAP-accredited clinical laboratory. The knowledge and experience that CMM and Xceed will gain by operating the system for research use in the real-world clinical laboratory environment will benefit both parties as they move forward together on diagnostic applications in oncology and possibly other diseases.
The Ziplex System is currently available for research purposes only, however Xceed said it plans to submit its first diagnostic assays for individual patients to the US Food and Drug Administration in 2008.
"We are very pleased to be supporting Xceed's efforts to bring its clinical laboratory-friendly Ziplex System to the marketplace. The CMM will provide Xceed the opportunity to bring new array-based tests to the clinical community. As translational medicine moves from the research laboratory to the clinic, technology that is affordable, reliable and automated will be critical. We believe the Ziplex System is uniquely positioned to fulfill this need," said Dr. Daniel H. Farkas, Executive Director of the CMM.
Researchers interested in obtaining more information about the Ziplex System may contact CMM directly at 616.391.4330 or visit http://www.cmmdx.org/researchers .
About the CMM
The Center for Molecular Medicine, a joint venture between Grand Rapids, Mich.-based Spectrum Health and Van Andel Institute (VAI), brings West Michigan a cutting-edge laboratory that will aid in early diagnoses and enhance personalized medicine. It offers 21st century molecular technologies for investigation of complex diseases like cancer, heart disease, mental illness and other conditions at the DNA, RNA and protein levels. The Center brings new and increased opportunities for diagnostics and pharmaceutical companies to conduct trials in a world-class medical and clinical research environment. For more information, visit http://www.cmmdx.org.
|SOURCE Center for Molecular Medicine|
Copyright©2007 PR Newswire.
All rights reserved